Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vidofludimus calcium by Immunic for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
Vidofludimus calcium is under clinical development by Immunic and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According...
Vidofludimus calcium by Immunic for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
Vidofludimus calcium is under clinical development by Immunic and currently in Phase II for Post-Acute Sequelae of COVID 2019 (PASC...
Vidofludimus calcium by Immunic for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to...
Risk adjusted net present value: What is the current valuation of Immunic's Vidofludimus calcium?
Vidofludimus calcium is a small molecule commercialized by Immunic, with a leading Phase III program in Coronavirus Disease 2019 (COVID-19)....
Vidofludimus calcium by Immunic for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
Vidofludimus calcium is under clinical development by Immunic and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According...
Risk adjusted net present value: What is the current valuation of Immunic's Vidofludimus calcium?
Vidofludimus calcium is a small molecule commercialized by Immunic, with a leading Phase III program in Relapsing Remitting Multiple Sclerosis...